Anviron - "Targeting the Cancer Glycome"

Drug developer focused on rare, difficult to treat cancers: #PancreaticCancer #TNBC #Her2

[Anviron - "Targeting the Cancer Glycome" @anviron1]

Pancreatic Cancer has a superpower. It becomes a factory for producing stem cells which resist chemotherapies. ANV221 was awarded FDA Orphan Drug Designation for Pancreatic Cancer by deactivating this stem cell program and shrinking tumors superior to Gemcitabine. #pdac #fda

[Anviron - "Targeting the Cancer Glycome" @anviron1]

@adamfeuerstein Anviron is here and we brought our experimental pancreatic cancer drug. Come say 'hello'!

[Anviron - "Targeting the Cancer Glycome" @anviron1]

Researchers identified the enzyme responsible for drug resistance in advanced HER2+ breast cancer. We can confirm drug resistance is safely reversible with our drug, APPB. Excited to share our decision to extend APPB to advanced, HER2+ breast cancer. #mbc https://t.co/AKD5BwrSeV

[Anviron - "Targeting the Cancer Glycome" @anviron1]

On 3/20, patent 12,129,272 awarded for our experimental drug treating adv #PDAC, #her2, and #tnbc cancers. Thank you to our partners @uthsc, @UTRF, @Caltech, & @UCSD. Also to patent officers @uspto for your continued service supporting important innovations, we appreciate you!

[Anviron - "Targeting the Cancer Glycome" @anviron1]

Oncotarget pub found low Her2 tumor growth was reversed by anti-her2 trastuzumab when combined with DPAGT1 inhibitors. This paradox was confirmed by Anviron, we found Her2 gene upregulation in TNBC treated with ANV221, opening the door to potent, targeted treatment for #TNBC

[Bradley Morrison @bcmorrison]

Congratulations to @anviron1 team for their recently granted patent, "Glycosyl Transferase Inhibitors”. One important step in the fight against difficult-to-treat, advanced solid tumor cancers.

[Anviron - "Targeting the Cancer Glycome" @anviron1]

Anviron team is proud to announce that the United States Patent Office has granted our extended claims for patent 11,597,743, "GLYCOSYLTRASNFERASE INHIBITORS FOR TREATMENT OF SOLID TUMORS", to support Anviron's experimental drug candidate, ANV221.

[Anviron - "Targeting the Cancer Glycome" @anviron1]

The degree our drug candidate, ANV221, re-sensitizes Her2-positive, drug-resistant breast cancers to trastuzumab and other anti-Her2 drugs is being studied. Results will be announced this summer.

[Anviron - "Targeting the Cancer Glycome" @anviron1]

Anviron team has produced a brief summary of exciting progress with drug-resistant, Her2+ breast cancers. Thank you to the Anviron team for putting this together. https://t.co/bL8lw1C73O

[Anviron - "Targeting the Cancer Glycome" @anviron1]

Thank you Daniel Morgan!

[Daniel Morgan @dtmorgan18]

Earnest Post: Cancer is terrible. My mom is a 3x survivor

A buddy is working on a new tech with/ Caltech & U of Tennessee for drug-resistant cancers; the current focus is on her2 breast cancer

I'd like to connect him w/ oncologists

Consider reposting for reach. More info 👇

[Anviron - "Targeting the Cancer Glycome" @anviron1]

Please join the Anviron team in recognizing World Pancreatic Cancer Day! Show your support by participating in a PurpleStride 2024 event near you. - https://t.co/Ms5pHCcfgG

[Anviron - "Targeting the Cancer Glycome" @anviron1]

The Anviron team is resolute in our support for our Israeli friends and colleagues. Our hearts go out to the victims of these horrific attacks and we strongly condemn the barbaric violence against innocent civilians.

[Anviron - "Targeting the Cancer Glycome" @anviron1]

Cancers hijack the synthesis of cell surface membrane proteins so tumors can hide from our immune system & resist chemotherapy. We are developing drugs that disrupt this cancer behavior and are excited to announce our candidate ANV221 was awarded a US Patent.

[Bradley Morrison @bcmorrison]

Another exciting annoucement from @anviron1. US Patent Office has issued patent for lead candidate ANV221 that recently received FDA Orphan Drug Designation for the treatment of #pancreaticcancer #pdac - https://t.co/JxEY504GbT

[Anviron - "Targeting the Cancer Glycome" @anviron1]

@MassChallenge has invited Anviron to the 2023 U.S. Early Stage Cohorts. Congrats to the 186 #startups that have been invited to participate!
👉 MEET THE COHORTS: https://t.co/ew9btlwnOG
🎉 50% of startups have at least 1 #BIPOC founder

[Anviron - "Targeting the Cancer Glycome" @anviron1]

@AmericanCancer announced the 5 year survival rate for #PancreaticCancer increased to 12%. Thanks to all that support those suffering from this horrific disease. @lustgartenfdn @PanCAN - https://t.co/xCFXDdowKb

[Anviron - "Targeting the Cancer Glycome" @anviron1]

Thank you @PanCAN for all you do to raise awareness for this devastating disease during Pancreatic Cancer Awareness Month! . Your hard word is appreciated!

[Anviron - "Targeting the Cancer Glycome" @anviron1]

Congratulations to Eli Lilly and the #retevmo team for their recent FDA approval of Selpercatinib for the treatment of non-small cell lung cancer. Well done! https://t.co/jbe5yy50nL

[Anviron - "Targeting the Cancer Glycome" @anviron1]

@OrbiMed Congratulations to the Iecuire team!

[Anviron - "Targeting the Cancer Glycome" @anviron1]

We look forward to joining our colleagues @FierceBiotech next week in Boston. #oncology